Alvotech birtir uppgjör fyrir árið 2023 og kynnir nýjustu áfanga í rekstri félagsins
March 20, 2024 16:15 ET
|
Alvotech
Heildartekjur á árinu 2023 voru 93,4 milljónir dollara, sem er 10% aukning frá fyrra áriSölutekjur á árinu 2023 voru 48,7 milljónir dollara, samanborið við 24,8 milljónir dollara á árinu 2022, og voru...
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
March 20, 2024 16:15 ET
|
Alvotech
Total Revenues in 2023 were $93.4 million, up 10% from previous yearProduct Revenues in 2023 were $48.7 million, compared to $24.8 million in 2022, with Q4 2023 product revenues of $18.9 million, up...
Alvotech Appoints Interim Chief Quality Officer
February 29, 2024 16:05 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join...
Alvotech gengur að tilboði um sölu hlutabréfa að fjárhæð um 22,8 milljarðar króna (um 166 milljónir dala) á genginu 2.250 krónur (16,41 dalir) á hlut
February 26, 2024 04:25 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að félagið hafi gengið að tilboði frá hópi fagfjárfesta og viðurkenndra gagnaðila um sölu á 10.127.132 almennum hlutabréfum í félaginu að verðmæti um 22,8...
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
February 26, 2024 04:25 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has accepted an offer from...
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
February 26, 2024 04:25 ET
|
Alvotech
REYKJAVIK, Iceland, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...